For example, co-treatment of RANKL inhibitor osteoprotegerin (OPG) and docetaxel was found to significantly decrease tumor burden and osteolytic lesions in a murine model of prostate cancer bone metastasis [219], whereas sole treatment with OPG was reported to diminish the proportion of RANKL-positive osteoblasts and bone metastasis following castration of mice [220]. This evidence concerns the gene TNFRSF11B and prostate cancer.